SEC Comment Letter 0000000000-24-008283 to Aspira Women's Health Inc. (AWHL)
Aspira Women's Health Inc.
Date: July 22, 2024 · CIK: 0000926617 · Accession: 0000000000-24-008283
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280848
Letter
July 22, 2024 Nicole Sandford Chief Executive Officer Aspira Women's Health Inc. 12117 Bee Caves Road, Building III, Suite 100 Austin, TX 78738 Re:Aspira Women's Health Inc. Registration Statement on Form S-3 Filed July 17, 2024 File No. 333-280848 Dear Nicole Sandford: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Sean Reid, Esq.
Show Raw Text
July 22, 2024
Nicole Sandford
Chief Executive Officer
Aspira Women's Health Inc.
12117 Bee Caves Road, Building III, Suite 100
Austin, TX 78738
Re:Aspira Women's Health Inc.
Registration Statement on Form S-3
Filed July 17, 2024
File No. 333-280848
Dear Nicole Sandford:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Sean Reid, Esq.